title: Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice.
abstract: OBJECTIVE
  The anti-inflammatory effects of O-1602 and cannabidiol (CBD), the ligands of G protein-coupled receptor 55 (GPR55), on experimental acute pancreatitis (AP) were investigated.
  
  
  METHODS
  Acute pancreatitis was induced in C57BL mice by intraperitoneal injection of 50 μg/kg cerulein hourly, with a total of 6 times. Drugs (O-1602, 10 mg/kg, or CBD, 0.5 mg/kg) were given by intraperitoneal injection 2 times at 30 minutes before the first injection and immediately before the fifth cerulein injection. At 3 hours after the last injection, the blood, the lungs, and the pancreas were harvested for the pancreatic enzyme activity, myeloperoxidase activity, and pro-inflammatory cytokines measurement; and the expressions of GPR55 mRNA and protein in the pancreas were detected.
  
  
  RESULTS
  Cannabidiol or O-1602 treatment significantly improved the pathological changes of mice with AP and decreased the enzyme activities, IL-6 and tumor necrosis factor α; levels, and the myeloperoxidase activities in plasma and in the organ tissues. G protein-coupled receptor 55 mRNA and protein expressed in the pancreatic tissue, and the expressions were decreased in the mice with AP, and either CBD or O-1602 attenuated these changes to a certain extent.
  
  
  CONCLUSIONS
  Cannabidiol and O-1602 showed anti-inflammatory effects in mice with AP and improved the expression of GPR55 in the pancreatic tissue as well.
authors: Institute of Digestive Disease, Department of Pathophysiology, Tongji University School of Medicine, Shanghai, China.
authors: Kun
authors: K
authors: Li
authors: Jia-yan
authors: JY
authors: Feng
authors: Yong-yu
authors: YY
authors: Li
authors: Birol
authors: B
authors: Yuece
authors: Xu-hong
authors: XH
authors: Lin
authors: Liang-ying
authors: LY
authors: Yu
authors: Yan-na
authors: YN
authors: Li
authors: Ya-jing
authors: YJ
authors: Feng
authors: Martin
authors: M
authors: Storr
mesh_terms: D000208:Acute Disease; D000681:Amylases / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015153:Blotting, Western; D002185:Cannabidiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D002108:Ceruletide; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D018836:Inflammation Mediators / Q000097:blood; D007274:Injections, Intraperitoneal; D015850:Interleukin-6 / Q000097:blood; D008049:Lipase / Q000097:blood; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010195:Pancreatitis / Q000097:blood / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D009195:Peroxidase / Q000097:blood; D012333:RNA, Messenger / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D043882:Receptors, Cannabinoid / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; C526692:GPR55 protein, mouse; D018836:Inflammation Mediators; D015850:Interleukin-6; D012333:RNA, Messenger; D043882:Receptors, Cannabinoid; D014409:Tumor Necrosis Factor-alpha; D002185:Cannabidiol; C568537:O-1602 compound; D002108:Ceruletide; D009195:Peroxidase; D008049:Lipase; D000681:Amylases